UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED 31ST DECEMber,2002
Rs in millions
Quarter Ended
Nine Months Ended
Year Ended 31.03.2002
(Audited)
31.12.2002
31.12.2001
31.12.2002
31.12.2001
1.Net Sales & Income from Operations
3870.0
3669.1
11842.9
10071.5
14005.1
2. Other Income
58.7
145.9
147.4
273.4
283.6
3. Total Expenditure
a) (Increase)/ decrease in Stock-in -trade
(337.4)
(320.3)
(538.6)
(366.9)
(850.9)
b) Consumption of Materials
1961.8
1930.7
5733.7
4936.7
6907.5
c) Staff Cost
182.3
158.6
537.5
462.0
632.5
d) Other Expenditure
1174.2
1173.2
3417.1
2969.8
4272.1
4. Interest
3.5
7.8
7.5
15.0
21.0
5. Depreciation
79.0
48.5
216.5
143.5
212.8
6. Profit (+) / Loss (-) before Tax (1+2-3-4-5)
865.3
816.5
2616.6
2184.8
3093.7
7. Provision for Taxation
200.7
190.0
609.1
510.0
742.5
8. Net Profit (+) / Loss (-)(6-7)
664.6
626.5
2007.5
1674.8
2351.2
9. Paid-up Equity Share Capital
599.7
599.7
599.7
599.7
599.7
10. Reserves excluding Revaluation Reserves ( as per balance-sheet of previous accounting year)
8197.0
11. Earning per Share ** Not Annualised
*11.08
*10.45
*33.47
*27.93
34.62
Notes : 1. Provision for tax includes deferred taxation.
2. The Company is exclusively in the pharmaceutical business segment.
3. The figures of the previous year have been regrouped to render them comparable with the figures of current year.
4. The above results were taken on record at the meeting of the Board of Directors held on 18th January, 2003.
